Login / Signup

Rituximab retention rate in systemic sclerosis: a long term real-life multicenter study.

Giacomo DE LucaEnrico De LorenzisCorrado CampochiaroFabio CacciapagliaNicoletta Del PapaElisabetta ZanattaPaolo AiròMaria Grazia LazzaroniDilia GiuggioliMaria De SantisGabriella AlonziStefano StanoMarco BindaBeatrice MoccaldiAntonio TonuttiSilvia CavalliVeronica BataniGerlando NatalelloFlorenzo IannoneMaria Antonietta D'AgostinoLorenzo DagnaMarco Matucci-CerinicSilvia Laura Bosello
Published in: Rheumatology (Oxford, England) (2024)
rituximab is a safe and effective treatment in SSc: clinical response emerged as the primary reason for rituximab discontinuation, and AEs had a limited impact on treatment persistence. The identification of specific disease features associated with a response to rituximab will be useful in the management of SSc-patients.
Keyphrases